These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 26359256

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP, Lima EN, Osório CA, do Socorro Maciel M, Baiocchi G, Bitencourt AG, Fanelli MF, Damascena AS, Soares FA.
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [Abstract] [Full Text] [Related]

  • 24. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [Abstract] [Full Text] [Related]

  • 25. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S, Yoshizawa N, Shigekawa T, Takeuchi H, Ogura H, Osaki A, Saeki T, Ueda Y, Yamane T, Kuji I, Sakahara H.
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [Abstract] [Full Text] [Related]

  • 26. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK.
    Acta Radiol; 2011 Feb 01; 52(1):21-8. PubMed ID: 21498321
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
    Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V.
    J Nucl Med; 2015 Jan 01; 56(1):31-7. PubMed ID: 25476537
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
    Marti-Climent JM, Dominguez-Prado I, Garcia-Velloso MJ, Boni V, Peñuelas I, Toledo I, Richter JA.
    Rev Esp Med Nucl Imagen Mol; 2014 Jan 01; 33(5):280-5. PubMed ID: 25066253
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.
    Kiyoto S, Sugawara Y, Hosokawa K, Nishimura R, Yamashita N, Ohsumi S, Mochizuki T.
    Asia Ocean J Nucl Med Biol; 2016 Jan 01; 4(1):3-11. PubMed ID: 27904868
    [Abstract] [Full Text] [Related]

  • 33. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
    Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R, Coombes RC, Aboagye EO.
    Clin Cancer Res; 2011 Dec 15; 17(24):7664-72. PubMed ID: 22028493
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.
    Radiology; 2015 Nov 15; 277(2):358-71. PubMed ID: 25915099
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M, Narui K, Kaneta T, Sugae S, Sakamaki K, Inoue T, Ishikawa T.
    Clin Nucl Med; 2017 Mar 15; 42(3):169-175. PubMed ID: 28072617
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 15; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.